Moderate Hepatic Impairment Clinical Trial
Official title:
An Open-label, Single-dose Study to Assess the Pharmacokinetics of Pexidartinib in Subjects With Moderate Hepatic Impairment Compared to Healthy Subjects
The pharmacokinetics of a single dose of pexidartinib was investigated in participants with impaired hepatic function and compared with healthy control participants with normal hepatic function.
Pexidartinib is an orally administered tyrosine kinase inhibitor, currently approved in the US for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not amenable to improvement with surgery. The primary objective of this study is to determine the plasma pharmacokinetics (PK) of pexidartinib after a single oral dose of 200 mg in participants with moderate hepatic impairment (HI) as defined by National Cancer Institute Organ Dysfunction Working Group (NCI-ODWG) criteria compared to the healthy controls participants with normal hepatic function. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02871570 -
A Study to Evaluate the Effect of IV Doses of Rivipansel in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function
|
Phase 1 | |
| Completed |
NCT05116826 -
Nitazoxanide Pharmacokinetic Parameters in Hepatic Impaired Patients
|
Phase 1 | |
| Completed |
NCT04995484 -
Belzutifan (MK-6482) Hepatic Impairment Study (MK-6482-020)
|
Phase 1 | |
| Completed |
NCT01012284 -
A Study of TMC207 in Patients With Moderately Impaired Hepatic Function
|
Phase 1 | |
| Completed |
NCT05610657 -
A Pharmacokinetic Study of Mitapivat in Participants With Moderate Hepatic Impairment Compared to Matched Healthy Control Participants With Normal Hepatic Function
|
Phase 1 | |
| Completed |
NCT04534699 -
Pharmacokinetics of KBP-5074 in Patients With Moderate Hepatic Impairment
|
Phase 1 | |
| Recruiting |
NCT05224609 -
A Study to Learn About the Study Medicine (Called Lorlatinib) in People With Liver Dysfunction
|
Phase 1 |